For research use only. Not for therapeutic Use.
Gunagratinib (Cat No.: I028479) is an orally bioavailable, selective pan-FGFR (fibroblast growth factor receptor) inhibitor targeting FGFR1–4. It is designed to block aberrant FGFR signaling involved in tumor growth, angiogenesis, and survival in cancers with FGFR mutations, fusions, or amplifications. Gunagratinib has demonstrated potent antitumor activity in preclinical models and is under clinical investigation for treating solid tumors, including cholangiocarcinoma, urothelial carcinoma, and lung cancer. Its broad FGFR coverage supports its potential as a precision oncology therapy.
| CAS Number | 2211082-53-8 |
| Synonyms | 3-[2-(3,5-dimethoxyphenyl)ethynyl]-5-(methylamino)-1-[(3S)-1-prop-2-enoylpyrrolidin-3-yl]pyrazole-4-carboxamide |
| Molecular Formula | C22H25N5O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H25N5O4/c1-5-19(28)26-9-8-15(13-26)27-22(24-2)20(21(23)29)18(25-27)7-6-14-10-16(30-3)12-17(11-14)31-4/h5,10-12,15,24H,1,8-9,13H2,2-4H3,(H2,23,29)/t15-/m0/s1 |
| InChIKey | QFUIJOBJAQBGDH-HNNXBMFYSA-N |
| SMILES | CNC1=C(C(=NN1C2CCN(C2)C(=O)C=C)C#CC3=CC(=CC(=C3)OC)OC)C(=O)N |
| Reference | [1]. Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
